We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading at $30.82 as of February 25th.
[caption id="attachment_425899" align="aligncenter" width="750"]Celldex Therapeutics Inc. (CLDX) is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. The company has initiated a second Phase III/registration trial for its lead compound,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.